Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Another Look: Understanding Tumor Infiltrating Lymphocytes (TIL) therapy currently being developed by Iovance

Ticker(s): IOVA

Who's the expert?

Name: Dr Marco Donia - MD | PhD

Institution: Center for Cancer Immune Therapy, Herlev Hospital

  • Associate Professor in Clinical Oncology & Junior Research Group Leader (TIL group) at Herlev Hospital, University of Copenhagen.
  • Involved in several aspects of TIL treatment, both translational and clinical research (currently five trials currently open at their site and he is the primary co-supervisor of all.)
  • Clinician-scientist with 50% time dedicated to clinical duties; works in an experimental cancer treatment unit and treats around 60 patients/month with cancer immunotherapy – the vast majority with melanoma.

Interview Questions
Q1.

Please describe your clinical practice as it relates to cancer immunotherapies.

Added By: c_admin
Q2.

Can you briefly explain TIL as a mechanism of action?

Added By: c_admin
Q3.

What are your thoughts on Tumor Infiltrating Lymphocytes (TIL) therapy currently being developed by Iovance?

Added By: c_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.